Use of recommended medications after myocardial infarction in Austria

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Guidelines advocate for long-term beta-blockers (BB), statins, and ACEI/ARBs post-myocardial infarction (MI).
• Real-world data on the utilization of these crucial medications after MI discharge are limited.
• Understanding adherence patterns is vital for optimizing secondary prevention in MI survivors.

Purpose of the Study:

• To assess the outpatient use of key cardiovascular medications following acute myocardial infarction (MI).
• To identify factors influencing the prescription of beta-blockers (BB), statins, and ACEI/ARBs in MI survivors.
• To evaluate the extent of secondary prevention medication uptake in a real-world Austrian cohort.

Main Methods:

• Retrospective analysis of Austrian sickness funds claims data for acute MI patients discharged in 2004.
• Identification of patients surviving at least 120 days post-MI.
• Ascertainment of outpatient drug use (ACEI/ARBs, BBs, statins, aspirin) and comorbidities via prescription data.

Main Results:

• Among 4,105 MI patients, 67% received ACEI/ARBs, 74% received BBs, and 67% received statins within 120 days.
• Only 41% of patients were prescribed all three major drug classes; 25% received one or none.
• Older age, severe mental illness, obstructive lung disease, and heart failure were associated with lower medication use.

Conclusions:

• Recommended secondary prevention medications are underutilized in Austrian MI survivors.
• There is a significant gap between guideline recommendations and actual prescribing practices.
• Establishing quality indicators and targeted interventions are crucial for enhancing post-MI care.